Nydia Roman

Recommended Articles

• The 5 Possible Causes of Multiple Sclerosis

  MS is the result of an abnormal response by the body’s immune system. This response results in an attack on the central nervous system — the brain, spinal cord, and optic nerve. Specifically, the immune system attacks the protective coating around the nerve fibers — myelin — creating scar...

• Comparative Value of PARP Inhibitors is Lacking, According to ICER Report

  The Institute for Clinical and Economic Review, also known as ICER, is a non-profit organization that analyzes the value of new medical tests, treatments, and drugs approved by the U.S. Food and Drug Administration (FDA). The goal of ICER is to use the value of these innovations and develop reports...

• Rita Wilson Shares Her Experience After Successful Breast Cancer Treatment

  When someone is cured of breast cancer, most people associate survival with a general feeling of celebration and happiness. But breast cancer isn't just about the medical treatment or the science behind the ability to kill off cancer cells successfully. When someone suffers from cancer, they are...

• Night Sweats and Lymphoma

  LymphomaLymphoma is a type of cancer that begins in the lymphatic system, particularly in the disease-fighting immune cells called lymphocytes. These cells are found in the bone marrow, lymph nodes, thymus, spleen, and other parts of the body. In lymphoma, lymphocytes are altered and tend to...

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...

• New Treatment for Celiac Disease Using Nanoparticles Is Underway

  Recently, investigators have found a potential way to develop a treatment for celiac disease, which, according to Cour Pharmaceuticals focuses on the autoimmune disease, along with other inflammatory diseases. The treatment has been approved for clinical trials in August, 2017, and these trials have...